You can buy or sell NERV and other stocks, options, ETFs, and crypto commission-free!
Minerva Neurosciences, Inc Common Stock, also called Minerva Neurosciences, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. Read More The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Seeking AlphaMar 12
Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q4 2018 Results - Earnings Call Transcript
Minerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2018 Earnings Conference Call March 12, 2019 8:30 AM ET Company Participants William Boni - Vice President of Investor Relations & Corporate Communications Remy Luthringer - Executive Chairman & Chief Executive Officer Rick Russell - President Geoff Race - Executive Vice President, Chief Financial Officer & Chief Business Officer Conference Call Participants Jason Butler - JMP Securities Joel Beatty - Citi Biren Amin - Jefferies Operator Welcome to the...
Yahoo FinanceMar 12
Minerva Neurosciences: 4Q Earnings Snapshot
WALTHAM, Mass. (AP) _ Minerva Neurosciences Inc. (NERV) on Tuesday reported a fourth-quarter loss of $13.2 million, after reporting a profit in the same period a year earlier. The Waltham, Massachusetts-based company said it had a loss of 34 cents per share. For the year, the company reported that its loss widened to $50.2 million, or $1.29 per share. Minerva Neurosciences shares have climbed 21 percent since the beginning of the year. The stock has climbed 42 percent in the last 12 months. _____ This ...
Stock Price, News, & Analysis for Minerva Neurosciences
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disor...
-$0.36 per share
-$0.34 per share